Geron Announces Appointment of New Members to its Board of Directors

Core Insights - Geron Corporation has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, enhancing its leadership team with experienced industry veterans [1][2][3] Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer, with its first-in-class telomerase inhibitor RYTELO (imetelstat) approved in the U.S. and EU for treating certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia [4] - The company is conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis and other hematologic malignancies [4] Leadership Experience - Patricia S. Andrews brings extensive experience, having served in various leadership roles, including CEO of Sumitomo Pharma Oncology and positions at Glenmark Pharmaceuticals and Oncolytics Biotech [2][3] - Constantine Chinoporos has held senior positions in business development and corporate finance at companies like Applied Therapeutics and Albireo Pharmaceuticals, and currently serves as a strategic advisor to Apollo Therapeutics [3] Strategic Focus - The new board members are expected to provide valuable insights as Geron executes its strategic priorities and drives commercial growth for RYTELO [2] - Both Andrews and Chinoporos expressed their commitment to supporting Geron's focused commercial strategy and long-term growth objectives [2][3]